Enobia has raised more than $145m from universities seed fund T2C2 (Technology, Transfer, Commercialisation, Capital) and venture capital firms.
Alexion Pharmaceuticals, a Nasdaq-listed drugs company, has agreed to buy peer Enobia Pharma for up to $1.1bn in cash from its venture consortium that includes universities fund T2C2. Canada-based Enobia developes therapeutics for serious bone disorders and the deal includes a $610m initial payment and up to $470m in performance fees. Enobia has raised more…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
